4Liaw YF, Chien RN, Yeh CT, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mulation during lamivudine therapy. Hepatology, 1999,30 : 567-572.
二级参考文献9
1Chin R, Locarnini S. Treatment of chronic hepatitis B: current challenges and future directions. Rev Med Virol, 2003, 13: 255-272.
2Marcellin P. Advances in therapy for chronic hepatitis B. Semin Liver Dis, 2002, 22 (Suppl 1): 33-36.
3Manns MP. Current state of interferon therapy in the treatment of chronic hepatitis B. Semin Liver Dis, 2002, 22(Suppl 1): 7-13.
4Kiyosawa K, Tanaka E. Strategy for lamivudine-resistant YMDD mutant-associated chronic hepatitis B. J Gastroenterol, 2001, 36:139-141.
5Johnson MA, Jenkins JM, Bye C. A study of pharmacokinetic interaction between lamivudine and alpha interferon. Eur J Clin Pharmacol, 2000, 56: 289-292.
6Liaw YF. Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. J Gastroenterol Hepatol,2002, 17 (Suppl 3): 333-337.
7Schalm S, De Man R, Janssen H. Combination and newer therapies for chronic hepatitis B. J Gastroenterol Hepatol, 2002, 17(Suppl 3):338-341.
